Search results for "Endocrine Gland"

Asperuloside Enhances Taste Perception and Prevents Weight Gain in High-Fat Fed Mice

2021

Asperuloside is an iridoid glycoside found in many medicinal plants that has produced promising anti-obesity results in animal models. In previous studies, three months of asperuloside administration reduced food intake, body weight, and adipose masses in rats consuming a high fat diet (HFD). However, the mechanisms by which asperuloside exerts its anti-obesity properties were not clarified. Here, we investigated homeostatic and nutrient-sensing mechanisms regulating food intake in mice consuming HFD. We confirmed the anti-obesity properties of asperuloside and, importantly, we identified some mechanisms that could be responsible for its therapeutic effect. Asperuloside reduced body weight …

Timing of Exercise Affects Glycemic Control in Type 2 Diabetes Patients Treated with Metformin

2018

Objective. The purpose of the study was to examine the acute effects of the timing of exercise on the glycemic control during and after exercise in T2D. Methods. This study included 26 T2D patients (14 women and 12 men) who were treated with metformin. All patients were tested on four occasions: metformin administration alone (Metf), high-intensity interval training (HIIT) performed at 30 minutes (EX30), 60 minutes (EX60), and 90 minutes (EX90) postbreakfast, respectively. Glucose, insulin, and superoxide dismutase (SOD) activity were examined. Results. Glucose decreased significantly after the exercise in EX30, EX60, and EX90. Compared with Metf, the decline in glucose immediately after th…

Efficacy and Renal Safety of Dapagliflozin in Patients with Type 2 Diabetes Mellitus Also Receiving Metformin: A Real-Life Experience.

2017

Introduction. This study aimed at evaluating the efficacy and safety of dapagliflozin in patients with type 2 diabetes (T2D) who also received metformin in clinical practice in Italy. Methods. This was a retrospective observational study and it included data from patients who received dapagliflozin 10 mg once daily in conjunction with metformin for 12 months (DAPA + MET). In those with inadequate glycemic control, insulin or glimepiride was added after 30 days (DAPA + MET + other glucose-lowering drugs). Efficacy assessments included glycosylated hemoglobin (HbA1c) levels at 6 and 12 months, as well as body mass index (BMI) and lipid parameters at 12 months. Safety was also assessed. Result…

Plasma corticosteroids, free fatty acids, insulin and glucose in maternal blood during delivery.

1970

Plasma-corticosteroids (PCS), free fatty acids (FFA), insulin and glucose were determined continously in maternal blood during the entire course of delivery, from the first stage of labour until 6 hours after delivery. A steep increase in the PCS and FFA concentration could be noticed from the onset of labour (PCS: 37,8±11.2 µg/100 ml;\(s_{\bar x} \),p≦0.01; FFA: 556±106.6 µVal/l;\(s_{\bar x} \),p≦0.01) to the birth of the child (PCS: 96.8±19,5 µg/100 ml;\(s_{\bar x} \),p≦0.01; FFA: 1129±220 µVal/l;\(s_{\bar x} \),p≦0.01) and basal levels were already reached 6 hours later (PCS: 36.0±18.5 µg/100 ml;\(s_{\bar x} \),p≦0.01; FFA: 538±192.8 µVal/l;\(s_{\bar x} \),p≦0.01). The rise of insulin an…

Editorial: Stem Cells in Endocrine Tumors

2021

Impaired glucose regulation, depressive symptoms, and health-related quality of life

2020

IntroductionThis study aims to investigate whether the associations between impaired glucose regulation and health-related quality of life are modified by severity or type of depressive symptoms.Research design and methodsFor this cross-sectional study, we included 1939 individuals (mean age 61.5 years) from the Helsinki Birth Cohort Study. Between 2001 and 2004, a standard 2-hour 75 g oral glucose tolerance test was applied to define normoglycemia, pre-diabetes, and newly diagnosed diabetes. Information on previously diagnosed diabetes was collected from national registers and questionnaires. Pre-diabetes was defined as having either impaired fasting glucose or impaired glucose tolerance. …

Markers of Anemia in Children with Type 1 Diabetes

2018

Aim. The aim of the study was to assess markers of anemia in type 1 diabetes (T1D) children, compare them to results obtained in the control group, and estimate their relation to BMI SDS. Methods. 94 (59% ♀) T1D children without other autoimmune disorders, aged 12.5 ± 4.1 years, T1D duration: 4.2 ± 3.6 years, HbA1c 7.3 ± 1.5% (57 ± 12.6 mmol/mol). Sex- and age-matched controls (43 children). In all children, anthropometric measurements, the blood count, iron turnover parameters, and vitamin B12 concentration were taken. Results. T1DM children had significantly higher red cell distribution width (RDW) (13.6 versus 12.6%; p<0.001), hepcidin (0.25 versus 0.12 ng/ml; p<0.001), and vitamin…

Characterization of Metabolically Healthy Obese People and Metabolically Unhealthy Normal-Weight People in a General Population Cohort of the ABCD St…

2017

There is actually no consensus about the possibility that in some instances, obesity may be a benign metabolically healthy (MH) condition as opposed to a normal-weight but metabolically unhealthy (MUH) state. The aim of this study was to characterize MH condition and to investigate possible associations with metabolic and cardiovascular complications. One thousand nineteen people (range of age 18–90 years) of the cohort of the ABCD_2 study were investigated. Participants were classified as normal weight (BMI < 24.9 kg/m2) or overweight-obese (BMI ≥25 kg/m2); they were also classified as MH in the presence of 0-1 among the following conditions: (a) prediabetes/type 2 diabetes, (b) hyperte…

Insulin degludec and insulin glargine 300 U/mL: Which of these two insulins causes less hypoglycemia?

2019

The interesting article by Yamabe et al.1 showed, using continuous glucose monitoring, that insulin degludec (I‐Deg) was associated with a high percentage of time with nocturnal hypoglycemia than with insulin glargine 300 U/mL (I‐G300; P = 0.02). However, we observe that some possible confounding factors might have influenced the results, such as differences in concomitant medications, use of the same titration protocol for both kinds of insulin or differences in glucose levels. This is also a recurrent problem in clinical trials, which sometime produce conflicting results. In fact, the study of Yamabe et al. is partly in agreement with some recently published clinical trials that gave diff…

Aromatase Inhibitors Plus Weight Loss Improves the Hormonal Profile of Obese Hypogonadal Men Without Causing Major Side Effects

2020

Objective: In obese men, the increased expression of the aromatase enzyme in adipose tissue leads to high conversion of androgens to estrogens contributing to hypogonadotropic hypogonadism (HHG). Our objective is to evaluate efficacy and safety of weight loss (WL) plus aromatase inhibitor (AI) therapy in severely obese men with HHG. We hypothesize that AI+WL will be more effective as compared to WL alone in improving the hormonal profile, thus muscle strength and symptoms of HHG (primary outcomes), with no significant adverse effects on lean mass, metabolic profile, and bone mineral density (secondary outcomes).Design: Randomized double-blind placebo-controlled pilot trial.Methods: Twenty-t…